The Board has appointed
"It has been an eventful quarter, and we are very pleased to welcome
Period July -
- Net sales amounted to
SEK 0.0 (0.0) million -
Operating loss amounted to
SEK -4.5 (-28.2) million -
Result after tax amounted to
SEK -3.5 (-28.2) million, corresponding toSEK -0.01 per share (-0.05) before and after dilution -
Cash flow from operating activities amounted to
SEK -23.8 (-26.5) million
Period January -
- Net sales amounted to
SEK 0.0 (0.0) million -
Operating loss amounted to
SEK -45.0 (-80.2) million -
Result after tax amounted to
SEK -44.0 (-80.2) million, corresponding toSEK -0.08 per share (-0.16) before and after dilution -
Cash flow from operating activities amounted to
SEK -95.2 (-80.1) million -
Cash and cash equivalents at the end of the period amounted to
SEK 398.3 (463.1) million - Number of employees at the end of the period was 7 (8)
- Number of shares at the end of the period was 532,687,650
All comparative amounts in brackets refer to the outcome during the corresponding period 2021.
Significant events during the quarter
- InDex got a new patent for cobitolimod granted in
Europe
Significant events after the reporting period
- InDex's Board of Directors named
Jenny Sundqvist as new CEO
Other events
- InDex received positive feedback from the Japanese regulatory authority, the PMDA, regarding the clinical development plan for cobitolimod
CEO statement
It has been an eventful quarter, the Board has appointed a new CEO and InDex has received great interest in cobitolimod at
Patient recruitment for the phase III study CONCLUDE with cobitolimod is underway and a number of clinics have been very active in enrolling patients. However, the study has had a slower start-up than expected with several underlying reasons. Many clinics are still handling the effects of the covid pandemic, which has and continues to result in longer administrative processes.
Based on the previously communicated successful interactions with the Japanese regulatory authority, the
In the beginning of October, InDex participated as an exhibitor at the United European Gastroenterology Week (UEGW) in
Our ongoing clinical pharmacokinetic study (PK study) with cobitolimod is progressing according to plan and the results are expected to be presented during the first quarter of 2023. The study will include at least 6 patients with moderate to severe ulcerative colitis treated with doses of 500 mg cobitolimod administered rectally. The aim of the study is to confirm that the systemic uptake of cobitolimod is limited, which has been shown in previous preclinical and clinical studies. A limited systemic uptake is a significant advantage compared to competing drugs for ulcerative colitis that act on the whole body and can cause severe side effects outside the inflamed colon.
On
On
During the quarter, we have continued with our appreciated investor presentations. For those of you who did not have the opportunity to watch the presentations live, the recordings are available on our website. We will present InDex tomorrow on
Johan Giléus, acting CEO
For more information:
Johan Giléus, acting CEO
Phone: +46 8 122 038 50
E-mail: johan.gileus@indexpharma.com
The full report is attached as a PDF and is available on the company's website https://www.indexpharma.com/en/financial-reports/
Publication
This information is information that
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III study CONCLUDE as a novel treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
InDex is based in
https://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-holding-ab--publ--interim-report-january---september-2022,c3671275
https://mb.cision.com/Main/9612/3671275/1688920.pdf
https://mb.cision.com/Public/9612/3671275/8ab8b9e7d336b4f0.pdf
(c) 2022 Cision. All rights reserved., source